Detecting drug-resistant tuberculosis quickly and accurately.
Point of care detection of fluroquinolone, bedaquiline and linezolid resistant Mycobacterium tuberculosis for rapid treatment decisions.
This study is working on a quick and easy test to help doctors find out if tuberculosis (TB) is resistant to important medications, so they can choose the best treatment for patients right away.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11043429 on NIH RePORTER |
What this research studies
This research focuses on developing rapid point-of-care tests to identify drug-resistant strains of tuberculosis (TB), specifically targeting resistance to fluoroquinolones, bedaquiline, and linezolid. By utilizing advanced molecular drug susceptibility tests (mDSTs) that employ nucleic acid amplification techniques, the study aims to detect mutations that confer resistance to these critical anti-TB drugs. The goal is to create a test that can be easily used in clinical settings, allowing healthcare providers to make informed treatment decisions without delay. This innovative approach seeks to prevent the loss of new TB treatments due to emerging drug resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis who may have or are suspected to have drug-resistant strains.
Not a fit: Patients with non-tuberculosis infections or those who do not have a confirmed diagnosis of tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate treatment decisions for patients with drug-resistant tuberculosis.
How similar studies have performed: Previous research has shown promise in developing molecular tests for TB drug resistance, indicating that this approach could be effective.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Alland, David — Rutgers Biomedical and Health Sciences
- Study coordinator: Alland, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.